Lamivudine

Generic Name
Lamivudine
Brand Names
Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
Drug Type
Small Molecule
Chemical Formula
C8H11N3O3S
CAS Number
134678-17-4
Unique Ingredient Identifier
2T8Q726O95
Background

A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication

For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions
Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities

First Posted Date
2005-11-21
Last Posted Date
2011-06-21
Lead Sponsor
CIPRA SA
Target Recruit Count
812
Registration Number
NCT00255840

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

First Posted Date
2005-10-06
Last Posted Date
2013-12-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
300
Registration Number
NCT00234091
Locations
🇰🇭

National Pediatric Hosp., Cambodia CIPRA CRS, Phnom Penh, Cambodia

🇰🇭

Social Health Clinic, Cambodia CIPRA CRS, Phnom Penh, Cambodia

🇹🇭

Prapokklao Hosp. CIPRA CRS, Chantaburi, Thailand

and more 6 locations

Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients

Phase 2
Completed
Conditions
Chronic Hepatitis B
First Posted Date
2005-09-27
Last Posted Date
2008-10-24
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
30
Registration Number
NCT00226447
Locations
🇨🇳

Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

First Posted Date
2005-09-19
Last Posted Date
2012-04-12
Lead Sponsor
Kirby Institute
Target Recruit Count
80
Registration Number
NCT00192660
Locations
🇦🇺

St. Vincent's Hospital, Sydney, New South Wales, Australia

Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)

Phase 3
Completed
Conditions
HIV Infection
First Posted Date
2005-09-12
Last Posted Date
2007-07-03
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
100
Registration Number
NCT00158470
Locations
🇻🇳

Binh Trieu Hospital, Ho Chi Minh City, Vietnam

🇻🇳

Tropical Diseases Hospital, Ho Chi Minh City, Vietnam

Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV

Phase 4
Completed
Conditions
Acquired Immunodeficiency Syndrome
First Posted Date
2005-09-05
Last Posted Date
2013-11-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
53
Registration Number
NCT00144157
Locations
🇿🇦

Boehringer Ingelheim Investigational Site, Soweto, South Africa

A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

Phase 3
Completed
Conditions
Acquired Immunodeficiency Syndrome
First Posted Date
2005-09-05
Last Posted Date
2013-11-03
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
407
Registration Number
NCT00144183
Locations
🇿🇦

Boehringer Ingelheim Investigational Site, Soweto, South Africa

3TC or No 3TC for HIV With 3TC Resistance

Phase 4
Suspended
Conditions
HIV Infections
First Posted Date
2005-09-02
Last Posted Date
2008-09-25
Lead Sponsor
University of British Columbia
Target Recruit Count
152
Registration Number
NCT00143728
Locations
🇨🇦

St. Boniface General Hospital, Winnipeg, Manitoba, Canada

🇨🇦

McMaster University, Hamilton, Ontario, Canada

🇨🇦

Sunnybrook Hospital, Toronto, Ontario, Canada

and more 6 locations

Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

Phase 3
Completed
Conditions
Chronic Hepatitis B
First Posted Date
2005-09-01
Last Posted Date
2008-10-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
160
Registration Number
NCT00140725
Locations
🇭🇰

GSK Investigational Site, Shatin, Hong Kong

Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen

Phase 3
Completed
Conditions
HIV Infections
First Posted Date
2005-08-26
Last Posted Date
2010-02-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
254
Registration Number
NCT00135382
Locations
🇵🇷

Local Institution, Rio Piedras, Puerto Rico

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy